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A consensus conference on cardio-renal syndromes (CRS) was held in Venice Italy, in September 2008 under the auspices of the Acute
Dialysis Quality Initiative (ADQI). The following topics were matter of discussion after a systematic literature review and the appraisal of
the best available evidence: deﬁnition/classiﬁcation system; epidemiology; diagnostic criteria and biomarkers; prevention/protection strat-
egies; management and therapy. The umbrella term CRS was used to identify a disorder of the heart and kidneys whereby acute or
chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Different syndromes were identiﬁed and classi-
ﬁed into ﬁve subtypes. Acute CRS (type 1): acute worsening of heart function (AHF–ACS) leading to kidney injury and/or dysfunction.
Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction.
Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic
reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic
conditions leading to simultaneous injury and/or dysfunction of heart and kidney. Consensus statements concerning epidemiology, diagnosis,
prevention, and management strategies are discussed in the paper for each of the syndromes.
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Cardiac and renal diseases are common and frequently coexist to
signiﬁcantly increase mortality, morbidity, and the complexity and
cost of care.
1,2 Syndromes describing the interaction between
heart and kidney have been deﬁned and classiﬁed
1,3–7 but never
as a result of a consensus process. Thus, there is limited appreci-
ation of epidemiology and standardized diagnostic criteria. More-
over, prevention and treatment is fragmented, single organ
centred, and not multidisciplinary in approach. As a result, timing
and quality of care may suffer. A consensus conference was orga-
nized under the auspices of the Acute Dialysis Quality Initiative
(ADQI) in Venice, Italy, in September 2008. It involved opinion
leaders and experts in nephrology, critical care, cardiac surgery,
and cardiology. In this manuscript, we present the ﬁndings of this
consensus conference.
Methods
The ADQI process was applied.
8 The ADQI methodology comprises a
systematic search for evidence, establishment of relevant clinical and
physiological outcomes, description of current practice and analysis
of areas lacking evidence and setting of a speciﬁc research agenda.
Before the conference, topics were selected and work groups
assembled. Groups identiﬁed the key questions and conducted a sys-
tematic literature search. During the conference, work groups
assembled in breakout sessions, as well as plenary sessions where
their ﬁndings were presented, debated, and reﬁned. Key questions
were identiﬁed by the group and subgroups deliberated on these ques-
tions, bringing forth recommendations to the group as a whole. Delib-
erations followed 3 days of discussion among 32 attendees. Summary
statements were then developed by the entire group as reported here.
Results
The Steering Committee assembled an expert panel, which was
divided into ﬁve smaller working groups: (i) deﬁnition and classiﬁ-
cation, (ii) epidemiology, (iii) diagnostic biomarkers, (iv) preven-
tion, and (v) treatment.
Deﬁnition and classiﬁcation
Need for consensus deﬁnition
We unanimously agreed that a consensus deﬁnition was needed to
highlight the coexistence of cardiac and renal disorders and to
identify the time course of heart–kidney interaction and the
primacy of the organ leading to the syndrome. The goal of this deﬁ-
nition would be to facilitate epidemiological studies, identify target
populations for intervention, develop diagnostic tools, prevent and
manage different syndromes.
Principles of deﬁnition and classiﬁcation
We chose a broad term, using the plural (cardio-renal syndromes,
CRS), to indicate the presence of multiple syndromes. We chose
subtypes to recognize primary organ dysfunction (cardiac vs.
renal) and acute vs. chronic time frame. We considered structural
and/or functional abnormalities of both organs necessary. We
added an additional subtype to capture systemic conditions
affecting both organs simultaneously. We chose deﬁnitions to
include accepted criteria published by national and international
societies.
Consensus deﬁnition and classiﬁcation of cardio-renal
syndromes
We considered deﬁnitions from the literature and used a speciﬁc
publication
4 as template. We deﬁned the broad term ‘cardio-renal
syndromes’ as ‘disorders of the heart and kidneys whereby acute
or chronic dysfunction in one organ may induce acute or chronic
dysfunction of the other’. We identiﬁed ﬁve subtypes of the syn-
dromes (Table 1). Their pathophysiological mechanisms are
described in Figure 1.
We chose the term CRS to indicate the bidirectional nature of
the various syndromes and to recognize that this term was already
established in the medical lexicon, despite lack of formal deﬁnition.
Acute cardio-renal syndrome (type 1)
Acute worsening of heart function leading to kidney injury and/or
dysfunction. This is a syndrome of worsening renal function (WRF)
complicating acute heart failure (AHF) and/or acute coronary syn-
drome (ACS). Between 27 and 40% of patients hospitalized for
acute de-compensated heart failure (ADHF) appear to develop
acute kidney injury (AKI)
2,9 and fall into this clinical entity. These
patients experience higher mortality and morbidity, and increased
length of hospitalization.
4
Chronic cardio-renal syndrome (type 2)
Chronic abnormalities in heart function leading to kidney injury or
dysfunction. This subtype refers to a more chronic state of kidney
disease complicating chronic heart disease. This syndrome is
common and has been reported in 63% of patients hospitalized
with congestive heart failure (CHF).
10,11
Acute reno-cardiac syndrome (type 3)
Acute worsening of kidney function leading to heart injury and/or
dysfunction. This subtype refers to abnormalities in cardiac func-
tion secondary to AKI. The pathophysiological mechanisms likely
go beyond simple volume overload and the recent consensus deﬁ-
nition of AKI
12 may help to investigate this syndrome further.
Chronic reno-cardiac syndrome (type 4)
Chronic kidney disease (CKD) leading to heart injury, disease, and/
or dysfunction. This subtype refers to disease or dysfunction of the
heart occurring secondary to CKD. There is a graded and indepen-
dent association between the severity of CKD and adverse cardiac
outcomes. In a recent meta-analysis,
13 an exponential relation
between the severity of renal dysfunction and the risk for all-cause
mortality was described with excess cardiovascular deaths consti-
tuting over 50% of overall mortality.
Secondary cardio-renal syndromes (type 5)
Systemic conditions leading to simultaneous injury and/or dysfunc-
tion of heart and kidney. Although this subtype does not have
primary and/or secondary organ dysfunction, it refers to situations
where both organs are simultaneously affected by systemic ill-
nesses, either acute or chronic. Examples include sepsis, systemic
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Table 1 Cardio-renal syndromes: classiﬁcation, deﬁnitions, and work group statements
Syndromes Acute cardio-renal (type 1) Chronic cardio-renal (type 2) Acute reno-cardiac (type 3) Chronic reno-cardiac (type 4) Secondary CRS (type 5)
Organ failure
sequence
Deﬁnition Acute worsening of heart function
(AHF–ACS) leading to kidney injury
and/or dysfunction
Chronic abnormalities in heart
function (CHF-CHD) leading to
kidney injury or dysfunction
Acute worsening of kidney function
(AKI) leading to heart injury and/or
dysfunction
Chronic kidney disease (CKD) leading
to heart injury, disease and/or
dysfunction
Systemic conditions leading to
simultaneous injury and/or
dysfunction of heart and
kidney
Primaryevents Acute heart failure (AHF) or acute
coronary syndrome (ACS) or
cardiogenic shock
Chronic heart disease (LV
remodelling and dysfunction,
diastolic dysfunction, chronic
abnormalities in cardiac function,
cardiomyopathy)
AKI CKD Systemic disease (sepsis,
amyloidosis, etc.)
Criteria for
primary
events
ESC, AHA/ACC ESC, AHA/ACC RIFLE–AKIN KDOQI Disease-speciﬁc criteria
Secondary
events
AKI CKD AHF, ACS, arrythmias, shock CHD (LV remodelling and dysfunction,
diastolic dysfunction, abnormalities
in cardiac function), AHF, ACS
AHF, ACS, AKI, CHD, CKD
Criteria for
secondary
events
RIFLE–AKIN KDOQI ESC, AHA/ACC ESC, AHA/ACC ESC, AHA/ACC, RIFLE/AKIN
ESC, AHA/ACC KDOQI
Cardiac
biomarkers
Troponin, CK-MB, BNP, NT-proBNP,
MPO, IMA
BNP, NT-proBNP, C-reactive
protein
BNP, NT-proBNP BNP, NT-proBNP, C-reactive protein C-reactive protein,
procalcitonin, BNP
Renal
biomarkers
Serum cystatine C, creatinine, NGAL.
Urinary KIM-1, IL-18, NGAL, NAG
Serum creatinine, cystatin C, urea,
uric acid, C-reactive protein,
decreased GFR
Serum creatinine, cystatin C, NGAL.
Urinary KIM-1, IL-18, NGAL, NAG
Serum creatinine, cystatin C, urea, uric
acid, decreased GFR
Creatinine, NGAL, IL-18,
KIM-1, NAG
Prevention
strategies
Acutely decompensated heart failure
and acute coronary syndromes are
most common scenarios
Inciting event may be acute coronary
ischaemia, poorly controlled blood
pressure, and noncompliance with
medication and dietary sodium
intake
Randomized trials improving compliance
with heart failure care management
have reduced rates of hospitalization
and mortality, and a reduction in the
rates of acute cardio-renal syndrome
(type 1) can be inferred
A common pathophysiology
(neurohumoral, inﬂammatory,
oxidative injury) could be at work
to create organ dysfunction
Drugs that block the renin–
angiotensin system reduce the
progression of both heart failure
and CKD
It is unknown whether other classes
of drugs can prevent chronic
cardio-renal syndrome (type 2)
Acute sodium and volume overload
are part of the pathogenesis
It is unknown whether sodium and
volume overload is prevented with
different forms of renal
replacement therapy and if this will
result in lower rates of cardiac
decompensation
The chronic processes of cardiac and
renal ﬁbrosis, left ventricular
hypertrophy, vascular stiffness,
chronic Na and volume overload, and
other factors (neurohumoral,
inﬂammatory, oxidative injury) could
be at work to create organ
dysfunction
A reduction in the decline of renal
function and albuminuria has been
associated with a reduction in
cardiovascular events
The role of chronic uraemia, anaemia,
and changes in CKD-mineral and
bone disorder on the cardiovascular
s y s t e mi sk n o w ni nc h r o n i c
reno-cardiac syndrome
Potential systemic factors
negatively impact function
of both organs acutely
It is uncertain if reduction/
elimination of the key factors
(immune, inﬂammatory,
oxidative stress, thrombosis)
will prevent both cardiac and
renal decline.
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5lupus erythematosus, diabetes mellitus, amyloidosis, or other
chronic inﬂammatory conditions.
The ADQI working group recognized that many patients may
populate or move between subtypes during the course of their
disease. This classiﬁcation is not meant to ﬁx patients into one
immovable category (Figure 2). The group discussed and con-
sidered further sub-classiﬁcation, to include situations of transient
or reversible dysfunction, slowly or acutely progressive vs. stable
disease, however it chose a more parsimonious classiﬁcation
system.
Epidemiology of cardio-renal syndromes
Cardio-renal syndromes are characterized by signiﬁcant heart–
kidney interactions that share similarities in pathophysiology.
However, they are also likely to have important discriminating fea-
tures, in terms of predisposing or precipitating events, natural
history, and outcomes. A description of the epidemiology of
heart–kidney interaction, stratiﬁed by the CRS subtypes, is a criti-
cal initial step towards understanding the overall burden of disease
for each CRS subtype and vital in determining the presence of gaps
in knowledge and helping design future trials.
Acute cardio-renal syndrome (type 1)
A large body of literature has examined AKI due to worsening
heart function. Most studies are retrospective, secondary, and/or
post hoc analyses from large databases
2,9,14–18 or clinical trials of
drug therapy.
19,20 The term ‘WRF’ has been used to describe
the acute and/or sub-acute changes in kidney function in patients
ADHF or ACS. Its incidence estimates range between 19 and
45%. This broad range is largely attributable to variations in the
deﬁnitions of WRF, the observed time-at-risk and the population
under study. Most studies have found that WRF/AKI in ADHF/
ACS occurs early after presentation to hospital. In both ADHF
and ACS, the development of WRF/AKI has been associated
with greater short- and long-term all-cause and cardiovascular
mortality, prolonged duration of hospitalization,
9,15,21–23 increased
readmission rates,
24,25 accelerated progression to CKD stages
4–5,
17 and higher healthcare costs.
15 In addition, there seems to
be a biological gradient between severity of AKI and risk of
death.
24 Two studies have also shown the risk of poor outcome
persists regardless of whether WRF/AKI was transient or sus-
tained
22,25 and that even small acute changes in SCr (0.3 mg/dL)
can modify the risk of death.
19 Venous congestion may be an
important haemodynamic factor driving WRF in patient with
ADHF.
26 In ICU patients admitted with ADHF, WRF was associated
with greater central venous pressure (CVP) on admission and after
intensive medical therapy. This ﬁnding was apparent across the
spectrum of systemic blood pressure, pulmonary capillary wedge
pressure, cardiac index, and estimated glomerular ﬁltration rates.
26
Chronic cardio-renal syndrome (type 2)
Chronic heart disease and CKD frequently co-exist, and often the
clinical scenario does not permit to distinguish which disease came
ﬁrst. Large database studies do not distinguish between type 2 and
type 4 CRS. Nevertheless, between 45 and 63.6% of patients with
CHF have evidence of CKD.
11,27 In these studies, CKD was
associated with higher all-cause and cardiac-speciﬁc mortality.
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C. Ronco et al. 706Figure 1 Pathophysiology and deﬁnitions of the ﬁve subtypes of cardio-renal syndrome (modiﬁed by Ronco et al.
105).
ADQI consensus on ‘cardio-renal syndromes’ 707A ‘dose–response’ or graded association between decline in kidney
function and worse clinical outcome was generally noted. An
example of Type 2 CRS could be congenital heart disease (CHD).
In selected circumstances, long-standing CHD results in adaptive
alterations in kidney perfusion and neurohormonal activation. In a
study of 1102 adult patients with CHD, over 50% had evidence of
kidney dysfunction, and 9% had eGFR , 60 mL/min/1.73 m
2.
28
This latter group had a three-fold increase in mortality. Kidney dys-
function was observed even among CHD patients with simple ana-
tomical cardiac defects. A further challenge in describing the
epidemiology of type 2 CRS is that patients may also transition
between type 1 and type 2 CRS at various time points.
Acute reno-cardiac syndrome (type 3)
Deﬁning the epidemiology of acute reno-cardiac syndrome (type
3) is challenging for several reasons: (i) considerable heterogeneity
in predisposing conditions, (ii) different methods for deﬁning AKI,
(iii) variable baseline risk for the development of acute cardiac dys-
function (i.e. increased susceptibility in individuals with sub-clinical
cardiovascular disease), and (iv) failure of many clinical studies of
AKI to report the occurrence of acute cardiac dysfunction as out-
comes. Accordingly, incidence estimates and clinical outcomes of
acute cardiac dysfunction secondary to AKI are largely context
and disease-speciﬁc. The group deliberated that RIFLE/AKIN cri-
teria should be used to deﬁne AKI in the epidemiological studies.
12
An example of type 3 CRS could be the development of an ACS,
arrhythmia, or AHF after the onset of AKI or after acute glomeru-
lonephritis or acute cortical necrosis. Toxaemia, ﬂuid and sodium
retention, humoral mediators, and electrolyte derangements may
all contribute to acute dysfunction of the heart. Another case
could be cardiac surgery-associated AKI (CSA-AKI), where AKI
contributes to ﬂuid overload and to the development of latent
cardiac dysfunction. We also recognize that CSA-AKI may also rep-
resent type 1 CRS. This discrimination may have relevance as these
two presentations may be characterized by important differences in
epidemiology, risk factors, associated outcomes, and need for differ-
ing therapeutic interventions. The incidence of CSA-AKI has been
reported between 0.3 and 29.7%.
29–34 This large range in incidence
is attributed to the different deﬁnitions used.
35 However, the chal-
lenge in understanding the epidemiology of type 3 CRS is that its
incidence and associated risk factors fail to consider the inciting
event for CSA-AKI as either primarily AKI-related or heart-related.
Chronic reno-cardiac syndrome (type 4)
Several observational studies have evaluated the cardiovascular
event rates and outcomes in selected CKD populations.
36–48
Cardiac disease in CKD patients is common and cardiac-speciﬁc
mortality rates are 10- to 20-fold higher compared with age and sex-
matched non-CKD populations.
36,42,49,50 In non-renal replacement
therapy (RRT) dependent CKD patients, the prevalence of CVD
correlates with severity of CKD. Several observational studies
have found graded increases in the prevalence of CVD and heart
failure (HF), along with higher risk of subsequent cardiac events
associated with degree of decline in kidney function.
40,45–48 This
dose–response trend also translated into similar trends for the
risk of cardiac-speciﬁc and all-cause mortality.
36,40,43–45,48 Thus
CKD likely accelerates the risk for and development of CVD.
39,46,47
Secondary cardio-renal syndromes (type 5)
There are limited data on the epidemiology of secondary CRS
(type 5) due to the large number of potential contributing acute
and chronic systemic conditions. Accordingly, estimates of
Figure 2 In cardio-renal syndromes, there are two important aspects: the ﬁrst is the sequence of organ involvement and the second is the
bi-directionality of signalling leading to a vicious cycle. Another important aspect is the time frame in which the derangements occur (chronic or
acute). In all cases, there are moments in which prevention is possible, in others mitigation of the insult is potentially feasible, in others, thera-
peutic strategies must be implemented. At different times, a crucial role is played by imaging techniques and biomarkers enabling the clinician to
make an early diagnosis, establish illness severity, and to potentially predict outcomes. This ﬂowchart describes a series of conditions indicating
that patients may move from one type to another of cardio-renal syndromes.
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CRS are considered largely disease and/or context-speciﬁc and
may be time varying. We recognize that several chronic systemic
illnesses (i.e. diabetes mellitus, hypertension, amyloidosis) could
potentially fulﬁl the deﬁnition for CRS type 5, however, they
may also at particular times in their natural history, fulﬁl criteria
for other CRS subtypes. Importantly, in this context, there is cur-
rently an incomplete understanding of the pathophysiological
mechanisms of secondary heart–kidney interactions.
A prototypical condition that may lead to CRS type 5 is sepsis.
Sepsis is common and its incidence is increasing,
51,52 with a mor-
tality estimated between 20 and 60%.
51–53 Approximately 11–
64% of septic patients develop AKI that is associated with a
higher morbidity and mortality.
54–60 Abnormalities in cardiac func-
tion are also common in sepsis.
61–63 Observational data have
found 30–80% of septic patients have elevated cardiac-speciﬁc
troponins,
64–70 that often correlate with reduced left ventricular
function.
62,64,69,70 Acute kidney injury and myocardial injury/dys-
function in severe sepsis/septic shock are exceedingly common,
yet there is a lack of integrative and epidemiological studies that
have speciﬁcally examined for insight on its pathophysiology, inci-
dence, risk identiﬁcation, and associated outcomes.
Diagnosis and biomarkers of cardio-renal
syndromes
The consensus group deliberated on the role of biomarkers in the
diagnosis of the different types of the syndrome. The intention was
to integrate biomarkers into the diagnosis of the various CRS,
especially those that deal with AKI on top of acute cardiac
disease. If biomarkers are to be clinically useful in these settings,
physicians must be able to answer the following questions: (i)
can biomarkers be used to (early) identify and classify CRS? (ii)
Can biomarkers be used to risk-stratify patients with regard to
reversibility? (iii) Can biomarkers be used as targets for treatment?
(iv) Can biomarkers be used to monitor the effects of treat-
ment?
6,63–69 (v) Can imaging of the heart and kidneys be combined
effectively with biomarkers across the spectrum of diagnosis and
treatment of CRS?
Natriuretic peptides and heart failure
B-type natriuretic peptides (BNP and NT-proBNP) are established
diagnostic tools in ADHF
71 and represent independent predictors
of cardiovascular events and overall mortality in critical illness,
72
ACS,
73 and stable HF.
74 Natriuretic peptides (NPs) are elevated
in patients with CRS (type 1) in which AKI occurs as a conse-
quence of ADHF. Moreover, they have shown prognostic utility
in patients with various stages of renal insufﬁciency,
75,76 demon-
strating potential applications in CRS types 2 and 4. Although
many previous studies support the usefulness of BNP in the diag-
nosis and management of HF patients,
77,78 the relationship
between BNP, renal function, and the severity of HF is less clear.
Patients with CKD have higher levels of BNP and NT-proBNP
than age- and gender-matched subjects without reduced renal
function, even in the absence of clinical CHF.
79 Although these
higher levels of NPs have been attributed to reduced renal clear-
ance, there is likely some contribution from other mechanisms.
80,81
Biomarkers of renal injury
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) seemsto be one
of the earliest kidney markers of ischaemic or nephrotoxic injury in
animal models and is detected in the blood and urine of humans
soon after AKI.
82–88 In a recent study, a single measurement of
urinary NGAL was able to differentiate those with subsequent
AKI, with a sensitivity and speciﬁcity of 90 and 99%, respectively.
Neutrophil gelatinase-associated lipocalin could be used as an
earlier marker of impending WRF during the treatment of ADHF.
Cystatin C
Cystatin C appears to be a better predictor of glomerular function
than serum creatinine in patients with CKD. In AKI, urinary
excretion of cystatin C has been shown to predict the requirement
for RRT earlier than creatinine.
89,90
Kidney injury molecule-1
Kidney injury molecule-1 (KIM-1) is a protein detectable in the
urine after ischaemic or nephrotoxic insults to proximal tubular
cells.
91–93 Urinary KIM-1 seems to be highly speciﬁc for ischaemic
AKI and not for pre-renal azotemia, CKD, or contrast induced
nephropathy.
94
N-acetyl-b-(D)glucosaminidase
N-acetyl-b-(D)glucosaminidase is a lysosomal brush border enzyme
found in proximal tubular cells.
94–96 N-acetyl-b-(D)glucosamini-
dase has been shown to function as a marker of kidney injury,
reﬂecting particularly the degree of tubular damage.
94 It is not
only found in elevated urinary concentrations in AKI and CKD,
but also in diabetic patients, patients with essential hypertension,
and HF.
97–99
Interleukin-18
Interleukin-18 (IL-18) is a pro-inﬂammatory cytokine detected in
the urine after acute ischaemic proximal tubular damage.
100 It dis-
plays good sensitivity and speciﬁcity for ischaemic AKI with an
AUC . 90%
101 with increased levels 48 h prior to increases in
serum creatinine.
102 Urinary NGAL and IL-18 have been studied
as joint biomarkers for delayed graft function following kidney
transplantation.
103
Of the biomarkers presented above, NGAL (urine and plasma)
and Cystatin C are most likely to be integrated into clinical practice
in the near future. Clinical trials will be needed to see if earlier
identiﬁcation of AKI and the use of speciﬁc treatment algorithms
based on these markers will improve prognosis.
Bioimpedance vector analysis
There is a general agreement that bioimpedance vector analysis
(BIVA) may contribute to a better deﬁnition of the patient’s
hydration status. This may be used in combination with NGAL
and BNP to guide ﬂuid management strategies. In this way, patients
will be kept within the narrow window of adequate hydration pre-
venting worsening of both kidney and heart function.
Imaging
Imaging techniques have an additional role with respect to the lab-
oratory biomarkers in CRS. They may enhance, extend, and reﬁne
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by suspected CRS, it is prudent to avoid the use of iodinated con-
trast media if not strictly necessary. The presence of coronary
disease should be excluded by stress echo or stress myocardial per-
fusion (SPECT/PET) in types III, IV, and V CRS and in types I and II
CRS when the primary cardiac disease is valvular, congenital, or
myopathic. Inthefuture,researchshouldbedirected towardexper-
imental studies that apply molecular imaging techniques (MRI and
MRS,PET,etc.)tothesearchforinvivospeciﬁcmarkersfordiagnosis
and severity evaluation of the different types of CRS. Also in the
future, non-invasive imaging techniques should be reﬁned to quan-
tify renal blood ﬂow. Such data can then be correlated with
cardiac and renal biomarkers and most importantly guide ongoing
therapy designed to optimize renal blood ﬂow and ultimately pre-
serve kidney function. As for type 1 CRS, venous congestion and
high CVP seem to be associated with impaired renal function and
independently related to all-cause mortality in a broad spectrum
of patients with cardiovascular disease.
104
Prevention of cardio-renal syndromes
The rationale for the prevention of CRS is based on the concept
that once the syndrome begins it is difﬁcult to interrupt, not com-
pletely reversible in all cases, and associated with serious adverse
outcomes. We approached prevention using a proposed classiﬁ-
cation system.
4,105,106
Acute cardio-renal syndrome (type 1)
The most important preventive approach in patients with de novo
HF consists of the basic preventive strategies of the American
Heart Association/American College of Cardiology for Stage A
and B HF. These call for blood pressure control, use of drugs
that block the renin–angiotensin–aldosterone system, beta-
adrenergic blockers (BB), coronary artery disease risk factor
modiﬁcation, and compliance with dietary and drug treatments.
As venous congestion seems to be an important haemodynamic
factor driving WRF
26 in ADHF, future studies should evaluate
whether a CVP-tailored therapy might prevent WRF in those
patients.
Chronic cardio-renal syndrome (type 2)
In this setting, therapies that improve the natural history of chronic
HF include angiotensin converting enzyme inhibitors (ACE-I),
angiotensin receptor blockers (ARB), BB, aldosterone receptor
blockers, combination of nitrates and hydralazine, and cardiac
re-synchronization therapy.
106,107
Acute reno-cardiac syndrome (type 3)
The clinical problem in many cases is sodium and water retention.
Avoidance of hypervolaemia should help prevent cardiac decom-
pensation. In addition, uremic changes, hyperkalaemia, and
mediators of inﬂammation can have adverse cardiac conse-
quences.
106,108 As mentioned previously, prototypical scenarios
for type 3 CRS include forms of AKI (e.g. rapidly progressive glo-
merulonephritis) that secondarily lead to LV dysfunction.
Contrast-induced AKI in most cases is asymptomatic
106,109 and
unlikely to cause cardiac dysfunction. However, some patients
with contrast-induced AKI develop progressive renal failure,
volume overload, and ADHF requiring intensive care treatment
and/or transient and sometimes permanent dialysis.
110
Chronic reno-cardiac syndrome (type 4)
Type 4 CRS is a common syndrome since it involves the pro-
gression of CKD, often due to diabetes mellitus and hypertension,
with accelerated calciﬁc atherosclerosis, progressive LVH, and the
development of diastolic and systolic dysfunction.
111 The core pre-
vention concept beyond attention to usual risk factor modiﬁcation
is that the reduction in the rate of progression of CKD may lead to
reduced rates of type 4 CRS.
Secondary cardio-renal syndrome (type 5)
A core concept is that treatment of the primary illness (diabetes
mellitus, amyloidosis, sepsis, rhabdomyolysis, haemorrhagic
shock, etc.) in general improves both heart and kidney function.
Management strategies of cardio-renal
syndromes
Although there are clinical guidelines for managing both HF and
CKD,
10,112,113 there are no agreed guidelines for managing patients
with cardio-renal and/or reno-cardiac syndromes.
114
Acute cardio-renal syndrome (type 1)
Both abnormal renal function and also a deterioration early in the
course of treatment of ADHF increase mortality. Thus, any treat-
ment for HF should have a neutral effect or preferably improve
renal function.
112
The management of ADHF is described in the recent ESC/
ESICM guidelines.
112 Vasodilators
115 and loop diuretics are
widely recommended in cases of ADHF and in CRS type
1. However, loop diuretics predispose to electrolyte imbalances,
and hypovolaemia leading to neurohumoral activation, reduced
renal glomerular ﬂow with further rises in serum urea and creati-
nine.
116 Vasodilators (e.g. nesiritide) may also affect renal func-
tion
117 and in some cases exacerbate renal injury. Vasopressin
receptor 2 antagonists can improve hyponatraemia, but without
any clear survival beneﬁt.
118 If congestion coincides with low
blood pressure, inotropic agents should be considered.
In cardiogenic shock, treatments are designed to increase
cardiac output and restore renal blood ﬂow. Although inotropic
drugs, typically dobutamine or dopamine, may tide patients over,
they are often associated with increased mid-term mortality.
119
Other agents include phosphodiesterase inhibitors, milrinone,
and levosimendan.
112 Extracorporeal ultraﬁltration may be useful
in ADHF associated with diuretic resistance. If systemic hypoten-
sion persists, then norepineprine may be considered, along with
elective ventilation and/or intra-aortic balloon pumping. Depend-
ing upon pre-existing co-morbidity and the underlying aetiology,
left ventricular assist devices as a bridge to transplantation or
cardiac surgery may be appropriate.
120 It should be mentioned
that over-treatment with loop diuretics, ACE-I, and/or spironolac-
tone may induce AKI.
Chronic cardio-renal syndrome (type 2)
Therapeutic approaches to patients with CHF are complex and
involve the elimination and treatment of the underlying cause
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CHF progression. Self-care management is an important strategy in
CHF, encompassing adherence to treatment, symptom recog-
nition, and lifestyle changes (diet and nutrition, smoking cessation,
exercise training).
112
Angiotensin converting enzyme inhibitors,
121 beta-blockers,
122
ARBs,
123 and aldosterone antagonists
124 signiﬁcantly reduce mor-
tality and morbidity in CHF. The optimal approach is to combine
ACE-I and beta-blocker, titrate dosages, to which either an ARB
or aldosterone antagonist is subsequently added depending on
clinical condition and patient characteristics. In patients unable to
tolerate these agents, hydralazine and nitrates may be an
option.
112 Digoxin and diuretics improve symptoms in CHF but
have no effect on mortality.
119
Cardiac re-synchronization therapy is now recommended for
symptomatic CHF patients (NYHA III–IV) with poor left ventricu-
lar ejection fraction (LVEF) and QRS prolongation,
112 as are
implantable cardiac deﬁbrillators for both survivors of cardiac
arrest and/or sustained ventricular arrhythmias and also for symp-
tomatic CHF patients with impaired LVEF. In selected patients who
do not respond to treatment, mechanical assist devices and/or
cardiac transplantation may be appropriate.
120
Therapy of CHF with concomitant renal impairment is still not
evidence-based, as these patients are generally excluded from
CHF trials.
121–124 Typically, these patients are hypervolemic, and
more intensive diuretic treatment is needed.
113 Thiazide diuretics
may be less effective, and loop diuretics are preferred.
113 To
improve natriuresis, loop diuretic infusions are more potent, and
combinations with amiloride, aldosterone antagonists, or metola-
zone may be considered,
124 as increasing doses of loop diuretics
are associated with worse outcomes.
125 In refractory cases, RRT
may be required.
Angiotensin converting enzyme inhibitor and ARB initiation may
cause deterioration in renal function, which is frequently transient
and reversible. Patients with CKD or renal artery stenosis are at a
higher risk, and careful monitoring is recommended. If renal func-
tion declines, then other secondary causes such as excessive diur-
esis, persistent hypotension, prescription of nephrotoxic agents or
underlying renovascular disease should be excluded. Hyperkalae-
mia occurs with these agents and dietary restriction may be
required.
121,123,124
Anaemia is often present in patients with type 2 CRS, and cor-
rection of anaemia may improve symptoms without increasing sur-
vival.
112 Renal dysfunction is associated with altered drug
clearances, and some drugs, e.g. digoxin and allopurinol, require
dose adjustment, and the risk of spontaneous haemorrhage with
warfarin is increased.
Acute reno-cardiac syndrome (type 3)
As previously discussed, type 3 CRS has only recently been recog-
nized as a clinical entity, hence there is little known about the
treatment of this complication. Since a typical clinical scenario
would include AKI following contrast exposure, or following cardi-
ovascular surgery (CSA-AKI), prevention likely affords a better
chance to improve outcome than treating established disease. To
prevent contrast nephropathy, many potential preventive strat-
egies have been studied, and available evidence indicates that
isotonic ﬂuids have been the most successful intervention to
date, with conﬂicting data surrounding N-acetylcysteine.
126,127
Recently, Solomon et al.,
128 using a more sensitive deﬁnition of
AKI, identiﬁed a possible role for the low-osmolar, non-ionic
monomer iopamidol. Germane to the discussion of CRS, they
identiﬁed that patients suffering AKI secondary to contrast were
almost twice as likely to suffer downstream adverse events, includ-
ing cardiovascular events, in the year following the contrast
exposure, indicative of the serious consequences of type 3 CRS.
In terms of prevention of CSA-AKI, in a recent prospective,
double-blind study of patients with left ventricular dysfunction
undergoing cardiac surgery, nesiritide was associated with
improved post-operative renal function compared with patients
without nesiritide, thus suggesting a renoprotective property.
129
Chronic reno-cardiac syndrome (type 4)
The aetiology of HF in CKD is multifactorial. Despite cardioprotec-
tive strategies such as ACE-Is and/or beta-blockers only a minority
of dialysis patients are prescribed these drugs.
130 Antihypertensives
have been thought to increase intradialytic hypotension, but this
has not been proven.
131
Progressive CKD often leads to sodium retention due to
reduced renal excretion,
113 and similarly during haemodialysis
due to dietary noncompliance, inappropriately high dialysate
sodium and inability to achieve target or ‘dry’ weight.
132 Besides
preventing hypervolaemia and a positive sodium balance, the
other key management strategies include correcting anaemia and
minimizing vascular calciﬁcation.
113,114
Conclusions
The aim of the ADQI consensus conference on CRS was to facili-
tate better understanding of their epidemiology, opportunities for
early diagnosis through biomarkers, development of preventive
strategies, and application of evidence-based management strat-
egies (where available). A further aim was to allow identiﬁcation
of gaps in the literature and provide direction for future research
including clinical trials. We have deﬁned ﬁve syndromes that can
now be the target of future studies, described series of biomarkers
which may facilitate the identiﬁcation and treatment of such syn-
dromes and have outlined general strategies for prevention and
management. We hope this document will serve as starting point
for focused research into the care of these conditions which
affect so many people worldwide.
Funding
The ADQI consensus conference was supported by the non proﬁt
organization AARVI (Associazione Amici del Rene di Vicenza) and its
research branch IRRIV (International Renal Research Insitute of
Vicenza). Funding to pay the Open Access publication charges for
this article was provided by AARVI-IRRIV (Associazione Amici del
Rene di Vicenza and International Renal Research Institute of Vicenza).
Conﬂict of interest: none declared.
References
1. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database
and treatment options. Heart Fail Rev 2004;9:195–201.
ADQI consensus on ‘cardio-renal syndromes’ 7112. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, Loh E,
Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, pre-
dictors at admission, and impact of worsening renal function among patients
hospitalized with heart failure. J Am Coll Cardiol 2004;43:61–67.
3. Isles C. Cardiorenal failure: pathophysiology, recognition and treatment. Clin
Med 2002;2:195–200.
4. Ronco C, House AA, Haapio M. Cardiorenal syndrome: reﬁning the deﬁnition of
a complex symbiosis gone wrong. Intensive Care Med 2008;34:957–962.
5. Liang KV, Williams AW, Greene EL, Redﬁeld MM. Acute decompensated heart
failure and the cardiorenal syndrome. Crit Care Med 2008;36(Suppl. 1 ):S75–S88.
6. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardi-
orenal syndrome: ’Guyton revisited’. Eur Heart J 2005;26:11–17.
7. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat
Clin Pract Nephrol 2007;3:637.
8. Kellum JA, Bellomo R, Ronco C. Acute Dialysis Quality Initiative (ADQI):
methodology. Int J Artif Organs 2008;31:90–93.
9. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O’Connor
C M, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic impor-
tance of different deﬁnitions of worsening renal function in congestive heart
failure. J Card Fail 2002;8:136–141.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis
2002;39(Suppl. 2 1):S1–S266.
11. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR,
Wynne J. High prevalence of renal dysfunction and its impact on outcome in
118,465 patients hospitalized with acute decompensated heart failure: a
report from the ADHERE database. J Card Fail 2007;13:422–430.
12. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classiﬁcation
system for acute renal failure. Curr Opin Crit Care 2002;8:509–514.
13. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F,
Garg AX. Chronic kidney disease and mortality risk: a systematic review. JA m
Soc Nephrol 2006;17:2034–2047.
14. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S,
Kapeliovich M, Agmon Y, Markiewicz W, Aronson D. Inhospital and 1-year mor-
tality of patients who develop worsening renal function following acute
ST-elevation myocardial infarction. Am Heart J 2005;150:330–337.
15. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD,
Horwitz RI. Correlates and impact on outcomes of worsening renal function
in patients . or ¼65 years of age with heart failure. Am J Cardiol 2000;85:
1110–1113.
16. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, Hennen J.
Readmission after hospitalization for congestive heart failure among Medicare
beneﬁciaries. Arch Intern Med 1997;157:99–104.
17. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW,
Allison JJ. Long-term risk of mortality and end-stage renal disease among the
elderly after small increases in serum creatinine level during hospitalization for
acute myocardial infarction. Arch Intern Med 2008;168:609–616.
18. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis
of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008;
168:987–995.
19. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L,
Pfeffer MA, Solomon SD. Increase in creatinine and cardiovascular risk in
patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol
2006;17:2886–2891.
20. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW,
Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the
ESCAPE trial. J Am Coll Cardiol 2008;51:1268–1274.
21. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence
and impact of worsening renal function in patients hospitalized with decompen-
sated heart failure: results of the prospective outcomes study in heart failure
(POSH). Eur Heart J 2006;27:1216–1222.
22. Logeart D, Tabet JY, Hittinger L, Thabut G, Jourdain P, Maison P, Tartiere JM,
Solal AC. Transient worsening of renal function during hospitalization for
acute heart failure alters outcome. Int J Cardiol 2008;127:228–232.
23. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B,
Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L.
Worsening renal function in patients hospitalised for acute heart failure: clinical
implications and prognostic signiﬁcance. Eur J Heart Fail 2008;10:188–195.
24. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG,
Krumholz HM. Worsening renal function: what is a clinically meaningful
change in creatinine during hospitalization with heart failure? J Card Fail 2003;
9:13–25.
25. Latchamsetty R, Fang J, Kline-Rogers E, Mukherjee D, Otten RF, LaBounty TM,
Emery MS, Eagle KA, Froehlich JB. Prognostic value of transient and sustained
increase in in-hospital creatinine on outcomes of patients admitted with acute
coronary syndrome. Am J Cardiol 2007;99:939–942.
26. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC,
Young JB, Tang WH. Importance of venous congestion for worsening of renal
function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:
589–596.
27. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE,
Aban IB, Shlipak MG. Chronic kidney disease associated mortality in diastolic
versus systolic heart failure: a propensity matched study. Am J Cardiol 2007;99:
393–398.
28. Dimopoulos K, Diller GP, Koltsida E, Pijuan-Domenech A, Papadopoulou SA,
Babu-Narayan SV, Salukhe TV, Piepoli MF, Poole-Wilson PA, Best N,
Francis DP, Gatzoulis MA. Prevalence, predictors, and prognostic value of
renal dysfunction in adults with congenital heart disease. Circulation 2008;117:
2320–2328.
29. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, Stitt LW,
Heidenheim AP, Myers ML, Moist L. Perioperative N-acetylcysteine to prevent
renal dysfunction in high-risk patients undergoing cabg surgery: a randomized
controlled trial. J Am Med Assoc 2005;294:342–350.
30. Leacche M, Rawn JD, Mihaljevic T, Lin J, Karavas AN, Paul S, Byrne JG. Outcomes
in patients with normal serum creatinine and with artiﬁcial renal support for
acute renal failure developing after coronary artery bypass grafting. Am J
Cardiol 2004;93:353–356.
31. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent
association between acute renal failure and mortality following cardiac
surgery. Am J Med 1998;104:343–348.
32. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP,
Landolfo K. Acute renal failure following cardiac surgery. Nephrol Dial Transplant
1999;14:1158–1162.
33. Bove T, Calabro MG, Landoni G, Aletti G, Marino G, Crescenzi G, Rosica C,
Zangrillo A. The incidence and risk of acute renal failure after cardiac surgery.
J Cardiothorac Vasc Anesth 2004;18:442–445.
34. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A,
Mangano DT. Renal dysfunction after myocardial revascularization: risk factors,
adverse outcomes, and hospital resource utilization. The Multicenter Study of
Perioperative Ischemia Research Group. Ann Intern Med 1998;128:194–203.
35. Hoste EA, Cruz DN, Davenport A, Mehta RL, Piccinni P, Tetta C, Viscovo G,
Ronco C. The epidemiology of cardiac surgery-associated acute kidney injury.
Int J Artif Organs 2008;31:158–165.
36. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J,
Rocco M, Toto R, Windus D, Ornt D, Levey AS. Cardiac diseases in mainten-
ance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65:
2380–2389.
37. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovas-
cular disease and mortality in a community-based cohort with mild renal insufﬁ-
ciency. Kidney Int 1999;56:2214–2219.
38. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic
implications of renal insufﬁciency in asymptomatic and symptomatic patients
with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681–689.
39. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ.
Chronic kidney disease and the risk for cardiovascular disease, renal replace-
ment, and death in the United States Medicare population, 1998 to 1999.
J Am Soc Nephrol 2005;16:489–495.
40. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease
and the risks of death, cardiovascular events, and hospitalization. N Engl J Med
2004;351:1296–1305.
41. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM,
Stehouwer CD. Mild renal insufﬁciency is associated with increased cardiovascu-
lar mortality: The Hoorn Study. Kidney Int 2002;62:1402–1407.
42. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial
infarction among patients on long-term dialysis. N Engl J Med 1998;339:799–805.
43. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S,
Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S,
van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spec-
trum of patients with heart failure. Circulation 2006;113:671–678.
44. Mahon NG, Blackstone EH, Francis GS, Starling RC III, Young JB, Lauer MS. The
prognostic value of estimated creatinine clearance alongside functional capacity
in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol
2002;40:1106–1113.
45. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ,
Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL. Independent components
of chronic kidney disease as a cardiovascular risk state: results from the Kidney
Early Evaluation Program (KEEP). Arch Intern Med 2007;167:1122–1129.
46. McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC,
Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW,
C. Ronco et al. 711aVassalotti JA, Whaley-Connell AT. CKD and cardiovascular disease in screened
high-risk volunteer and general populations: the Kidney Early Evaluation Program
(KEEP) and National Health and Nutrition Examination Survey (NHANES)
1999–2004. Am J Kidney Dis 2008;51(4 Suppl. 2):S38–S45.
47. McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC,
McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J,
Whaley-Connell AT, Brenner RM, Bakris GL. Chronic kidney disease, prevalence
of premature cardiovascular disease, and relationship to short-term mortality.
Am Heart J 2008;156:277–283.
48. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufﬁciency and sub-
sequent death resulting from cardiovascular disease in the United States. JA m
Soc Nephrol 2002;13:745–753.
49. Johnson DW, Craven AM, Isbel NM. Modiﬁcation of cardiovascular risk in
hemodialysis patients: an evidence-based review. Hemodial Int 2007;11:1–14.
50. Herzog CA. Dismal long-term survival of dialysis patients after acute myocardial
infarction: can we alter the outcome? Nephrol Dial Transplant 2002;17:7–10.
51. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epi-
demiology of severe sepsis in the United States: analysis of incidence, outcome,
and associated costs of care. Crit Care Med 2001;29:1303–1310.
52. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the
United States from 1979 through 2000. N Engl J Med 2003;348:1546–1554.
53. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A,
Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R. Epidemiology
of sepsis and infection in ICU patients from an international multicentre cohort
study. Intensive Care Med 2002;28:108–121.
54. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J,
Marshall J, Parrillo JE, Skrobik Y, Kumar A. Acute kidney injury in septic shock:
clinical outcomes and impact of duration of hypotension prior to initiation of
antimicrobial therapy. Intensive Care Med 2009;35:871–881.
55. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM,
Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predic-
tive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003;14:
1022–1030.
56. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, Antunes F, Prata MM.
Acute renal failure in patients with sepsis. Crit Care 2007;11:411.
57. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU,
Loefﬂer M, John S. Acute renal failure in patients with severe sepsis and septic
shock—a signiﬁcant independent risk factor for mortality: results from the
German Prevalence Study. Nephrol Dial Transplant 2008;23:904–909.
58. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R,
Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results
of the SOAP study. Crit Care Med 2006;34:344–353.
59. Yegenaga I, Hoste E, Van Biesen W, Vanholder R, Benoit D, Kantarci G,
Dhondt A, Colardyn F, Lameire N. Clinical characteristics of patients developing
ARF due to sepsis/systemic inﬂammatory response syndrome: results of a pro-
spective study. Am J Kidney Dis 2004;43:817–824.
60. Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multi-
centre evaluation. Crit Care 2008;12:R47.
61. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF,
Mira JP, Chiche JD. Brain natriuretic peptide: a marker of myocardial dysfunction
and prognosis during severe sepsis. Crit Care Med 2004;32:660–665.
62. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK.
Cardiac troponins I and T are biological markers of left ventricular dysfunction
in septic shock. Clin Chem 2000;46:650–657.
63. Jardin F, Fourme T, Page B, Loubieres Y, Vieillard-Baron A, Beauchet A,
Bourdarias JP. Persistent preload defect in severe sepsis despite ﬂuid loading:
a longitudinal echocardiographic study in patients with septic shock. Chest
1999;116:1354–1359.
64. Fernandes CJ Jr, Akamine N, Knobel E. Cardiac troponin: a new serum marker of
myocardial injury in sepsis. Intensive Care Med 1999;25:1165–1168.
65. Spies C, Haude V, Fitzner R, Schroder K, Overbeck M, Runkel N, Schaffartzik W.
Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998;113:
1055–1063.
66. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit
Care Med 1999;27:1775–1780.
67. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, Gandini C.
Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospec-
tive study. Intensive Care Med 2000;26:31–37.
68. Ammann P, Fehr T, Minder EI, Gunter C, Bertel O. Elevation of troponin I in
sepsis and septic shock. Intensive Care Med 2001;27:965–969.
69. Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin I
predicts myocardial dysfunction and adverse outcome in septic shock. Int J
Cardiol 2004;95:13–17.
70. Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E,
Minder EI, Rickli H, Fehr T. Troponin as a risk factor for mortality in critically ill
patients without acute coronary syndromes. J Am Coll Cardiol 2003;41:
2004–2009.
71. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M,
Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R. Primary results of the Rapid
Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicen-
ter study of B-type natriuretic peptide levels, emergency department decision
making, and outcomes in patients presenting with shortness of breath. JA m
Coll Cardiol 2004;44:1328–1333.
72. Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D,
Szekeres T, Pacher R, Heinz G. N-terminal pro-B-type natriuretic peptide is
an independent predictor of outcome in an unselected cohort of critically ill
patients. Crit Care Med 2007;35:2268–2273.
73. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P,
White HD, Fox KA, Califf RM, Braunwald E. Prognostic value of serial B-type
natriuretic peptide testing during follow-up of patients with unstable coronary
artery disease. J Am Med Assoc 2005;294:2866–2871.
74. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP,
Tognoni G, Cohn JN. The comparative prognostic value of plasma neurohor-
mones at baseline in patients with heart failure enrolled in Val-HeFT. Eur
Heart J 2004;25:292–299.
75. Carr SJ, Bavanandan S, Fentum B, Ng L. Prognostic potential of brain natriuretic
peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond) 2005;
109:75–82.
76. Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P,
Maisel AS, Fitzgerald RL. Correlation and prognostic utility of B-type natriuretic
peptide and its amino-terminal fragment in patients with chronic kidney disease.
Am J Clin Pathol 2006;126:506–512.
77. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG,
Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF,
Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-
terminal Pro-BNP investigation of dyspnea in the emergency department
(PRIDE) study. Am J Cardiol 2005;95:948–954.
78. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG,
Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT,
Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R,
Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagno-
sis of heart failure: analysis from Breathing Not Properly (BNP) Multinational
Study. Circulation 2002;106:416–422.
79. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides.
Rev Cardiovasc Med 2003;4 (Suppl. 4):S13–S19.
80. Focaccio A, Volpe M, Ambrosio G, Lembo G, Pannain S, Rubattu S, Enea I,
Pignalosa S, Chiariello M. Angiotensin II directly stimulates release of atrial
natriuretic factor in isolated rabbit hearts. Circulation 1993;87:192–198.
81. Munagala VK, Burnett JC Jr, Redﬁeld MM. The natriuretic peptides in cardiovas-
cular medicine. Curr Probl Cardiol 2004;29:707–769.
82. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta
2000;1482:298–307.
83. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM,
Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T,
Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J. Endocytic
delivery of lipocalin–siderophore–iron complex rescues the kidney from ische-
mia–reperfusion injury. J Clin Invest 2005;115:610–621.
84. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P.
Identiﬁcation of neutrophil gelatinase-associated lipocalin as a novel early urinary
biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534–2543.
85. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil
gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin
nephrotoxicity. Am J Nephrol 2004;24:307–315.
86. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differ-
ential gene expression following early renal ischemia/reperfusion. Kidney Int
2003;63:1714–1724.
87. Schmidt-Ott KM, Mori K, Kalandadze A, Li JY, Paragas N, Nicholas T,
Devarajan P, Barasch J. Neutrophil gelatinase-associated lipocalin-mediated
iron trafﬁc in kidney epithelia. Curr Opin Nephrol Hypertens 2006;15:442–449.
88. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indi-
cator of active kidney damage. Kidney Int 2007;71:967–970.
89. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O,
Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin
C. Kidney Int 2004;66:1115–1122.
90. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG,
Philipp T, Kribben A. Prognostic value of tubular proteinuria and enzymuria in
nonoliguric acute tubular necrosis. Clin Chem 2004;50:552–558.
91. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury
Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule
injury. Kidney Int 2002;62:237–244.
ADQI consensus on ‘cardio-renal syndromes’ 711b92. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury
molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal
injury. Am J Physiol Renal Physiol 2004;286:F552–F563.
93. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney
injury molecule-1: a sensitive quantitative biomarker for early detection of
kidney tubular injury. Am J Physiol Renal Physiol 2006;290:F517–F529.
94. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H,
MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Jaber BL.
Urinay NAG activity and KIM-1 level are associated with adverse outcomes in
acute renal failure. J Am Soc Nephrol 2007;18:904–912.
95. Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D’Amico G.
Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dys-
function and a predictor of outcome in primary glomerulonephritis. Nephrol Dial
Transplant 2002;17:1890–1896.
96. Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NF.
Urinary N-acetyl- beta-D-glucosaminidase activities in patients with renal
disease. Br Med J 1975;3:408–411.
97. Uslu S, Efe B, Alatas O, Kebapci N, Colak O, Demirustu C, Yoruk A. Serum
cystatin C and urinary enzymes as screening markers of renal dysfunction in dia-
betic patients. J Nephrol 2005;18:559–567.
98. Harmankaya O, Ozturk Y, Basturk T, Obek A. Urinary excretion of
N-acetyl-beta-D-glucosaminidase in newly diagnosed essential hypertensive
patients and its changes with effective antihypertensive therapy. Int Urol
Nephrol 2001;32:583–584.
99. Matsushima H YH, Machiguchi T, Muso E, Matusyama E, Tamura T, Sasayama S.
Urinary albumin and TGF 1 levels as renal damage indices in patients with con-
gestive heart failure. Clin Exp Nephrol 2002;6:9.
100. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA,
Schrier RW, Edelstein CL. Impaired IL-18 processing protects caspase-1-
deﬁcient mice from ischemic acute renal failure. J Clin Invest 2001;107:
1145–1152.
101. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a
marker of human acute tubular necrosis. Am J Kidney Dis 2004;43:405–414.
102. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diag-
nostic marker for acute kidney injury and predicts mortality in the intensive care
unit. J Am Soc Nephrol 2005;16:3046–3052.
103. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelstein CL, Devarajan P.
Urine NGAL and IL-18 are predictive biomarkers for delayed graft function fol-
lowing kidney transplantation. Am J Transplant 2006;6:1639–1645.
104. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ,
Hillege HL. Increased central venous pressure is associated with impaired
renal function and mortality in a broad spectrum of patients with cardiovascular
disease. J Am Coll Cardiol 2009;53:582–588.
105. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome.
J Am Coll Cardiol 2008;52:1527–1539.
106. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of
chronic heart failure in the adult: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and Management
of Heart Failure). J Am Coll Cardiol 2005;46:e1–e82.
107. Boerrigter GC-BL, Abraham WT, St. John Sutton MG, Heublein D, Kruger KM,
Hill MR, McCullough PA, Burnett JC. Cardiac resynchronization therapy with
biventricular pacing improves renal function in heart failure patients with
reduced glomerular ﬁltration rate. Circulation 2007;116:II_405.
108. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. JA m
Soc Nephrol 2003;14:1549–1558.
109. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med 2008;
36 (Suppl. 4):S204–S211.
110. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal
failure after coronary intervention: incidence, risk factors, and relationship to
mortality. Am J Med 1997;103:368–375.
111. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardi-
ologist’s perspective. Curr Opin Nephrol Hypertens 2004;13:591–600.
112. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A,
Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I,
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P,
Zamorano JL, Auricchio A, Bax J, Bohm M, Corra U, della Bella P, Elliott PM,
Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M,
Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW,
Zannad F. ESC guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: the Task Force for the diagnosis and treatment of
acute and chronic heart failure 2008 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association of the ESC
(HFA) and endorsed by the European Society of Intensive Care Medicine
(ESICM). Eur J Heart Fail 2008;10:933–989.
113. Taal M, Tomson C. Clinical practice guidelines. Module 1. Chronic kidney
disease. http://www.renal.org/pages/pages/guidelines/current/ckd.php. Published
online ahead of print 7 August 2009.
114. Cassidy M, Richardson D, Jones C. Clinical practice guidelines. Module 2.
Complications. http://www.renal.org/pages/pages/guidelines/current/complications.
php. Published online ahead of print 7 August 2009.
115. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev 2007;12:
143–147.
116. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal
function with nesiritide in patients with acutely decompensated heart failure.
Circulation 2005;111:1487–1491.
117. Owan TE, Chen HH, Frantz RP, Karon BL, Miller WL, Rodeheffer RJ, Hodge DO,
Burnett JC Jr, Redﬁeld MM. The effects of nesiritide on renal function and
diuretic responsiveness in acutely decompensated heart failure patients with
renal dysfunction. J Card Fail 2008;14:267–275.
118. Ho JE, Teerlink JR. Role of tolvaptan in acute decompensated heart failure.
Expert Rev Cardiovasc Ther 2008;6:601–608.
119. Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Guize L, Alla F, Rouge P, Blin P,
Barlet MH, Paolozzi L, Vincent C, Desnos M, Samii K. Clinical proﬁle, contem-
porary management and one-year mortality in patients with severe acute
heart failure syndromes: The EFICA study. Eur J Heart Fail 2006;8:697–705.
120. Tatsumi E, Nakatani T, Imachi K, Umezu M, Kyo SE, Sase K, Takatani S,
Matsuda H. Domestic and foreign trends in the prevalence of heart failure
and the necessity of next-generation artiﬁcial hearts: a survey by the Working
Group on Establishment of Assessment Guidelines for Next-Generation Artiﬁ-
cial Heart Systems. J Artif Organs 2007;10:187–194.
121. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced
left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;
325:293–302.
122. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using
beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:
563–572.
123. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,
Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality
and morbidity in patients with chronic heart failure: the CHARM-Overall pro-
gramme. Lancet 2003;362:759–766.
124. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
The effect of spironolactone on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med
1999;341:709–717.
125. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM,
Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes
in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:
1064–1069.
126. Jasuja D, Mor MK, Hartwig KC, Palevsky PM, Fine MJ, Weisbord SD. Provider
knowledge of contrast-induced acute kidney injury. Am J Med Sci 2009;338:
280–286.
127. Palevsky PM. Deﬁning contrast-induced nephropathy. Clin J Am Soc Nephrol 2009;
4:1151–1153.
128. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS,
Sharma SK, Labinaz M, Gelormini JL, Barrett BJ. Contrast-induced nephropathy
and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009;4:
1162–1169.
129. Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr et al.
Effects of perioperative nesiritide in patients with left ventricular dysfunction
undergoing cardiac surgery:the NAPA Trial. J Am Coll Cardiol 2007;49:716–726.
130. Gowdak LH, Arantes RL, de Paula FJ, Krieger EM, De Lima JJ. Underuse of
American College of Cardiology/American Heart Association Guidelines in
hemodialysis patients. Ren Fail 2007;29:559–565.
131. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during
dialysis improves control but increases intradialytic hypotension. Kidney Int 2008;
73:759–764.
132. Davenport A, Cox C, Thuraisingham R. The importance of dialysate sodium
concentration in determining interdialytic weight gains in chronic hemodialysis
patients: the PanThames Renal Audit. Int J Artif Organs 2008;31:411–417.
C. Ronco et al. 711c